The company is now advancing into immuno-oncology (IO), led by Timo van den Berg, Senior Director of Immuno-Oncology, and Wim Dokter, Chief Scientific Officer. Byondis’ lead cancer ...

Despite recent advances in cancer treatment and immuno-oncology (IO) drugs, there remains a significant unmet need to effectively treat metastatic cancers. In response, Immunophotonics is ...